Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$5.97
-2.8%
$7.28
$2.71
▼
$10.31
$270.05M1.531.77 million shs568,766 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.86
-4.2%
$1.02
$0.71
▼
$3.31
$66.51M1.571.13 million shs440,610 shs
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
$1.43
-16.9%
$2.82
$0.49
▼
$4.19
$154.10M1.096.86 million shs14.48 million shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$3.69
-0.7%
$3.73
$2.83
▼
$15.74
$281.46M2.821.58 million shs1.55 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
-4.06%-10.63%-4.36%-24.10%+46.19%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+5.13%+21.22%-5.31%+0.22%-55.90%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
-1.71%-11.79%-38.79%+21.13%-41.50%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-0.27%+0.82%-0.27%-3.13%-67.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$5.97
-2.8%
$7.28
$2.71
▼
$10.31
$270.05M1.531.77 million shs568,766 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.86
-4.2%
$1.02
$0.71
▼
$3.31
$66.51M1.571.13 million shs440,610 shs
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
$1.43
-16.9%
$2.82
$0.49
▼
$4.19
$154.10M1.096.86 million shs14.48 million shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$3.69
-0.7%
$3.73
$2.83
▼
$15.74
$281.46M2.821.58 million shs1.55 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
-4.06%-10.63%-4.36%-24.10%+46.19%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+5.13%+21.22%-5.31%+0.22%-55.90%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
-1.71%-11.79%-38.79%+21.13%-41.50%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-0.27%+0.82%-0.27%-3.13%-67.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agenus Inc. stock logo
AGEN
Agenus
2.67
Moderate Buy$25.00318.90% Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.29
Hold$7.50777.19% Upside
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
2.00
Hold$5.00249.65% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
1.75
Reduce$8.20122.52% Upside

Current Analyst Ratings Breakdown

Latest CRDF, FULC, CYPH, and AGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
Boost Price TargetOverweight$4.90 ➝ $5.00
11/13/2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
Reiterated RatingSell (D-)
11/9/2026
Agenus Inc. stock logo
AGEN
Agenus
UpgradeSell (D+) ➝ Hold (C-)
11/9/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
UpgradeSell (E+) ➝ Sell (D-)
11/9/2026
Agenus Inc. stock logo
AGEN
Agenus
Reiterated RatingBuy$14.00 ➝ $16.00
10/23/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
DowngradeSell (D-) ➝ Sell (E+)
10/22/2026
Agenus Inc. stock logo
AGEN
Agenus
Reiterated RatingBuy
10/15/2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Reiterated RatingSell (D-)
10/8/2026
Agenus Inc. stock logo
AGEN
Agenus
UpgradeSell (D) ➝ Sell (D+)
10/8/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
UpgradeSell (E+) ➝ Sell (D-)
10/5/2026
Agenus Inc. stock logo
AGEN
Agenus
Reiterated RatingBuy$40.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agenus Inc. stock logo
AGEN
Agenus
$114.20M2.36N/AN/A($2.48) per share-2.41
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K112.73N/AN/A$0.36 per share2.38
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/AN/AN/AN/A$4.97 per shareN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M3.52N/AN/A$3.95 per share0.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agenus Inc. stock logo
AGEN
Agenus
$120K$0.669.04N/AN/A22.10%-27.16%26.91%N/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.55N/AN/AN/A-6,736.49%-111.80%-81.51%N/A
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
$4.82M$1.770.81N/AN/AN/A-18.08%-17.17%N/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$74.88M-$1.04N/AN/AN/AN/A-19.94%-19.16%N/A

Latest CRDF, FULC, CYPH, and AGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/A$1.13N/A$1.13N/A$9.91 million
11/12/2026Q3 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1380-$0.12+$0.0180-$0.12$0.08 million$0.17 million
11/12/2026Q3 2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.11-$0.11N/A-$0.14N/AN/A
11/5/2026Q3 2026
Agenus Inc. stock logo
AGEN
Agenus
-$0.2825$0.02+$0.3025$0.02$28.20 million$31.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.73
0.73
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.21
4.21
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/A
220.73
79.19
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
36.19
36.19

Institutional Ownership

CompanyInstitutional Ownership
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
30.46%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%

Insider Ownership

CompanyInsider Ownership
Agenus Inc. stock logo
AGEN
Agenus
6.50%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.80%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
3.50%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agenus Inc. stock logo
AGEN
Agenus
8145.25 million42.31 millionOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3177.79 million70.95 millionOptionable
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
40107.76 million103.99 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
5576.38 million70.81 millionOptionable

Recent News About These Companies

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agenus stock logo

Agenus NASDAQ:AGEN

$5.97 -0.17 (-2.83%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$0.85 -0.04 (-4.55%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cypherpunk Technologies stock logo

Cypherpunk Technologies NASDAQ:CYPH

$1.43 -0.29 (-16.86%)
As of 03:45 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$3.68 -0.03 (-0.67%)
Closing price 03:58 PM Eastern
Extended Trading
$3.68 0.00 (0.00%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.